Moderna Inc (MRNA)vsNeurogene Inc (NGNE)
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
NGNE
Neurogene Inc
$32.09
-0.99%
HEALTHCARE · Cap: $693.79M
Smart Verdict
WallStSmart Research — data-driven comparison
NGNE leads profitability with a 0.0% profit margin vs -141.4%. NGNE earns a higher WallStSmart Score of 26/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NGNE
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Intrinsic value data unavailable for NGNE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NGNE
The strongest argument for NGNE centers on Debt/Equity, Altman Z-Score, Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NGNE
The primary concerns for NGNE are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NGNE is a value play — different risk/reward profiles.
NGNE carries more volatility with a beta of 1.96 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NGNE generates stronger free cash flow (-24M), providing more financial flexibility.
Bottom Line
NGNE scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Neurogene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?